Sleep benefit in Parkinson's disease.
Identifieur interne : 004573 ( PubMed/Checkpoint ); précédent : 004572; suivant : 004574Sleep benefit in Parkinson's disease.
Auteurs : M. Merello [Argentine] ; A. Hughes ; C. Colosimo ; M. Hoffman ; S. Starkstein ; R. LeiguardaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Circadian Rhythm (drug effects), Female, Humans, Levodopa (pharmacology), Male, Middle Aged, Motor Activity (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Prospective Studies, Questionnaires, Sleep (drug effects), Time Factors.
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- drug effects : Circadian Rhythm, Motor Activity, Sleep.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Prospective Studies, Questionnaires, Time Factors.
Abstract
Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 +/- 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (chi 2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L-dopa dose to be postponed in approximately 50% of patients.
DOI: 10.1002/mds.870120405
PubMed: 9251067
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9251067Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sleep benefit in Parkinson's disease.</title><author><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Hughes, A" sort="Hughes, A" uniqKey="Hughes A" first="A" last="Hughes">A. Hughes</name></author><author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name></author><author><name sortKey="Hoffman, M" sort="Hoffman, M" uniqKey="Hoffman M" first="M" last="Hoffman">M. Hoffman</name></author><author><name sortKey="Starkstein, S" sort="Starkstein, S" uniqKey="Starkstein S" first="S" last="Starkstein">S. Starkstein</name></author><author><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9251067</idno><idno type="pmid">9251067</idno><idno type="doi">10.1002/mds.870120405</idno><idno type="wicri:Area/PubMed/Corpus">004645</idno><idno type="wicri:Area/PubMed/Curation">004645</idno><idno type="wicri:Area/PubMed/Checkpoint">004573</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sleep benefit in Parkinson's disease.</title><author><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Hughes, A" sort="Hughes, A" uniqKey="Hughes A" first="A" last="Hughes">A. Hughes</name></author><author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name></author><author><name sortKey="Hoffman, M" sort="Hoffman, M" uniqKey="Hoffman M" first="M" last="Hoffman">M. Hoffman</name></author><author><name sortKey="Starkstein, S" sort="Starkstein, S" uniqKey="Starkstein S" first="S" last="Starkstein">S. Starkstein</name></author><author><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Circadian Rhythm (drug effects)</term><term>Female</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Prospective Studies</term><term>Questionnaires</term><term>Sleep (drug effects)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Circadian Rhythm</term><term>Motor Activity</term><term>Sleep</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Questionnaires</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 +/- 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (chi 2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L-dopa dose to be postponed in approximately 50% of patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9251067</PMID><DateCreated><Year>1997</Year><Month>10</Month><Day>14</Day></DateCreated><DateCompleted><Year>1997</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>1997</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Sleep benefit in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>506-8</MedlinePgn></Pagination><Abstract><AbstractText>Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 +/- 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (chi 2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L-dopa dose to be postponed in approximately 50% of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Merello</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Colosimo</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Starkstein</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Leiguarda</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 1998 Jul;13(4):751-2</RefSource><PMID Version="1">9686788</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002940">Circadian Rhythm</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012890">Sleep</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9251067</ArticleId><ArticleId IdType="doi">10.1002/mds.870120405</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Argentine</li></country></list><tree><noCountry><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name><name sortKey="Hoffman, M" sort="Hoffman, M" uniqKey="Hoffman M" first="M" last="Hoffman">M. Hoffman</name><name sortKey="Hughes, A" sort="Hughes, A" uniqKey="Hughes A" first="A" last="Hughes">A. Hughes</name><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name><name sortKey="Starkstein, S" sort="Starkstein, S" uniqKey="Starkstein S" first="S" last="Starkstein">S. Starkstein</name></noCountry><country name="Argentine"><noRegion><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004573 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004573 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9251067
|texte= Sleep benefit in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9251067" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |